Results 21 to 30 of about 27,592 (211)
Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia [PDF]
The Korean Journal of Internal Medicine, 2023 Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels.
Jeongmin Lee, Seung-Hwan Lee
doaj +1 more source
Biocatalysis as Useful Tool in Asymmetric Synthesis: An Assessment of Recently Granted Patents (2014–2019) [PDF]
, 2019 The broad interdisciplinary nature of biocatalysis fosters innovation, as different technical fields are interconnected and synergized. A way to depict that innovation is by conducting a survey on patent activities.
Alcántara, Andrés R. +2 more
core +3 more sources
Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021
Frontiers in Cardiovascular Medicine, 2022 AimsAddition of ezetimibe to statin therapy is recommended by current guidelines when low-density lipoprotein cholesterol (LDL-C) targets are not achieved with statin monotherapy.
Julius L. Katzmann +7 more
doaj +1 more source
Journal of Lipid Research, 2009 This study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or cholesterol synthesis or coadministration of both agents. This was a randomized, double blind, placebo-
Thomas Sudhop +8 more
doaj +1 more source
New approaches in detection and treatment of familial hypercholesterolemia [PDF]
, 2015 Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that clinically leads to increased low density lipoprotein-cholesterol (LDL-C) levels. As a consequence, FH patients are at high risk for cardiovascular disease (CVD). Mutations
Hartgers, ML, Hovingh, GK, Ray, KK
core +3 more sources
International Journal of Cardiology: Heart & Vasculature, 2015 Background: Little is known concerning the effect of ezetimibe for secondary prevention in post-myocardial infarction (MI) patients. In this study, we investigated the secondary prevention effect of ezetimibe for post-MI patients.
Soichiro Ebisawa +14 more
doaj +1 more source
Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]
, 2017 Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah +13 more
core +1 more source
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. [PDF]
, 2018 AimsThis analysis assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in patients with or without metabolic syndrome (MetS) using pooled data from 10 phase 3 ODYSSEY trials.Materials and methodsData ...
Bujas-Bobanovic, Maja +6 more
core +1 more source
Physicians' Experiences as Patients with Statin Side Effects: A Case Series. [PDF]
, 2017 Physicians are among those prescribed statins and therefore, subject to potential statin adverse effects (AEs). There is little information on the impact of statin AEs on physicians affected by them. We sought to assess the character and impact of statin
Golomb, Beatrice Alexandra +2 more
core +2 more sources
Angewandte Chemie, EarlyView.Photocatalytic cross‐coupling: A redox‐neutral photochemical method enables direct C(sp2)─C(sp2) bond formation between phenols and heteroaryl halides using an organic dye and base. Complementary radical generation allows efficient cross‐coupling in up to 91% yield. Mechanistic studies, DFT, HTE, and machine learning rationalize and predict reactivity,
Matthew C. Carson +4 more
wiley +2 more sources